| Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients (NCT05252078) | Jiangxi Provincial Cancer Hospital | 2022-06-02 |
| Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL (NCT05186558) | The First Affiliated Hospital with Nanjing Medical University | 2022-05-15 |
| A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor (NCT05298683) | Hellenic Society of Hematology | 2022-05-01 |
| A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment (NCT05147493) | Hellenic Society of Hematology | 2022-04-01 |
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations (NCT05241873) | Blueprint Medicines Corporation | 2022-03-04 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC (NCT05153408) | Blueprint Medicines Corporation | 2022-01-13 |
| A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (NCT05160168) | Theseus Pharmaceuticals | 2022-01-03 |
| Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma (NCT05155215) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2021-12-31 |
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma (NCT04572451) | Yana Najjar | 2021-11-29 |
| Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer (NCT04807166) | Wenjun Cheng | 2021-08-24 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC (NCT04862780) | Blueprint Medicines Corporation | 2021-06-29 |
| Spanish Series of Patients Treated With the Radionuclide Lutetium177 (NCT04949282) | Sociedad Española de Medicina Nuclear e Imagen Molecular | 2021-05-10 |
| External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC (NCT04697446) | Blueprint Medicines Corporation | 2020-12-01 |
| Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer (NCT04556071) | Xiaoxiang Chen | 2020-11-06 |
| Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (NCT04566952) | Xiaoxiang Chen | 2020-10-28 |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT04222972) | Hoffmann-La Roche | 2020-07-24 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma (NCT04309084) | Celularity Incorporated | 2020-05-12 |
| Natural Killer Cell (CYNK-001) Infusions in Adults with AML (NCT04310592) | Celularity Incorporated | 2020-03-12 |
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) (NCT04249947) | Poseida Therapeutics, Inc. | 2020-02-28 |
| HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors (NCT03911388) | M.D. Anderson Cancer Center | 2019-09-12 |
| Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma (NCT04124198) | Christian von Buchwald | 2019-03-01 |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) (NCT03744676) | Juno Therapeutics, a Subsidiary of Celgene | 2018-11-29 |
| Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies (NCT03722186) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-13 |
| A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide (NCT03495921) | Gradalis, Inc. | 2018-08-21 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (NCT03037385) | Hoffmann-La Roche | 2017-03-17 |
| Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (NCT02909452) | Syndax Pharmaceuticals | 2016-09-20 |
| Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (NCT02690545) | UNC Lineberger Comprehensive Cancer Center | 2016-08-26 |
| Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors (NCT02897778) | Syndax Pharmaceuticals | 2016-08-24 |
| Administration of T Lymphocytes for Prevention of Relapse of Lymphomas (NCT02663297) | UNC Lineberger Comprehensive Cancer Center | 2016-06-07 |
| A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer (NCT02543645) | Celldex Therapeutics | 2015-10-01 |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma (NCT02386111) | Celldex Therapeutics | 2015-05-01 |
| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies (NCT02158858) | Constellation Pharmaceuticals | 2014-07-16 |
| Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial (NCT01995942) | Royal Marsden NHS Foundation Trust | 2013-06-07 |
| Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients (NCT01579253) | Ludwig-Maximilians - University of Munich | 2012-04-01 |
| Intended Use Study of the BD SurePath Plus™ Pap (NCT01234480) | Becton, Dickinson and Company | 2010-09-01 |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) (NCT01009593) | Abbott | 2010-01-01 |
| Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks (NCT01037049) | Royal Marsden NHS Foundation Trust | 2009-10-16 |
| A Trial In Patients With Advanced Cancer And Leukemia (NCT00878189) | Pfizer | 2009-06-25 |
| Low Rectal Cancer Study (MERCURY II) (NCT02005965) | Royal Marsden NHS Foundation Trust | 2007-08-13 |
| A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma (NCT00102609) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2005-04-01 |
| Vorasidenib Expanded Access Program (NCT05592743) | Servier | |